Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

July 17th 2023

Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.

Prognostic Markers in Peripheral Blood Shine Light on Future Directions in NSCLC

July 16th 2023

Joseph Christopher Murray, MD, discusses the role of prognostic markers in non–small cell lung cancer and how data from the EMPOWER trials will guide future directions in the space.

Treatment Options for Patients with Uncommon EGFR Mutations in NSCLC

July 14th 2023

Focused discussion on uncommon EGFR mutations in non–small cell lung cancer and concurrent treatment options in this setting.

Refining EGFR Classifications and Impact on Treatment for NSCLC

July 14th 2023

Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

Key Trials at ASCO 2023 Highlight Role of Perioperative Treatment Approaches in NSCLC

July 13th 2023

Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.

Despite Diagnostic Challenges, ADCs Are Poised to Expand Treatment Options in Lung Cancer

July 13th 2023

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

July 13th 2023

Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.

Novel Radiotherapy Supports Precision Medicine Advances in Lung and Bone Cancers

July 13th 2023

Adnan F. Danish, MD, discusses current unmet needs in the treatment of patients with stage IV lung and bone cancers, the benefits SCINTIX technology can provide for these patients, and how John Theurer Cancer Center plans to use this technology to improve patient outcomes and support further radiation therapy research.

Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

July 13th 2023

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Datopotamab Deruxtecan Plus Pembrolizumab Displays Efficacy in Advanced NSCLC With or Without Chemotherapy

July 12th 2023

Yasushi Goto, MD, PhD, delves into the details of the TROPION-Lung02 trial.

Dr Levy on the Correlation Between Upfront NGS and OS Benefit in NSCLC

July 11th 2023

Benjamin Philip Levy, MD, discusses the relationship between upfront next-generation sequencing and survival outcomes in non–small cell lung cancer.

THIO Followed by Cemiplimab Shows Early Promise in Advanced NSCLC

July 10th 2023

The sequential combination of 6-thio-2’-deoxyguanosine and cemiplimab provided a progression-free survival benefit in the first 2 patients with advanced non–small cell lung cancer enrolled to the part A safety lead-in portion of the phase 2 THIO-101 trial.

MET+ Expression May Be Predictive of Responses With Amivantamab/Lazertinib in Post-Osimertinib NSCLC

July 10th 2023

MET positivity according to immunohistochemistry showed predictive value for deriving durable responses with amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer whose disease progressed on or after osimertinib and are chemotherapy naïve.

CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes

July 10th 2023

Expert oncologists discuss long-term data updates from the CASPIAN trial and the associated implications on clinical practice.

Expert Insights on First-line Treatment Strategies in SCLC

July 10th 2023

An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.

Dr Santos on Frontline Therapies in ALK+ NSCLC

July 7th 2023

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; treasurer, Florida Society of Clinical Oncology, discusses first-line treatment options for patients with ALK-positive non–small cell lung cancer.

BLU-945 Plus Osimertinib Has Favorable Tolerability, Warrants Further Development in EGFR+ NSCLC

July 7th 2023

BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.

Zenocutuzumab Wins FDA Breakthrough Therapy Designation for Advanced NRG1+ NSCLC

July 7th 2023

The FDA has granted breakthrough therapy designation to zenocutuzumab for use as a potential therapeutic option in patients with advanced unresectable or metastatic, NRG1 fusion–positive non–small cell lung cancer following progression with prior systemic therapy.

Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary Care

July 7th 2023

A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.

Dr Simon on PD-L1 Inhibitors in NSCLC

July 6th 2023

George Simon, MD, FACP, FCCP, discusses findings from an FDA pooled analysis of PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non–small cell lung cancer.